Batm Advanced Communicat... Share Discussion Threads

[kooba] 13/12/2024 12:28

Resistance ..i dont care how Moti explained it ..there was a basis of them increasing their interest at a significantly reduced value than the previous funding....thats a down round.They say a lot to explain things that don't add up ...i would be weary of sucking it all up when facts don't support the narrative.

[kemche] 13/12/2024 10:43

What is happening with the buybacks?

[resistance1] 13/12/2024 10:37

Kooba the lower value was explained by Moti as a benefit. One of the existing core funders didnt have further funds for this raise and so BATM stepped in at an advantageous rate

[kooba] 12/12/2024 12:56

Last raise Oct 2023..when they moved to 43.6% ...it was effectively a down round by all intents and purposes as Batm increased exposure for a lower value.https://www.proactiveinvestors.co.uk/companies/news/1030562/batm-invests-us-3-5m-in-diagnostics-business-ador-1030562.html

[wizzkid211] 12/12/2024 11:49

I wonder if batm will increase their holding in the next round of cash demand from ADOR which i think is bound to happen soon last cash raised December 22.
holding now 44%.

[kooba] 12/12/2024 09:22

I would imagine a partner or distribution alliance would want full validation and EU approval to be interested...at that juncture ADOR would be in a stronger position to talk terms with those interested...hoping the company sets out a realistic timetable to achieve those real milestones when the company can look to finally generate revenues...in the meantime it is unclear when and who will have to put more money in as they are likely burning the cash raised just over a year ago at pace.

[fse] 11/12/2024 16:54

Might want to look at this.



Just got to get it out there that always seems to be the problem, still it’s a huge market.

[fse] 11/12/2024 16:08

I was particularly worried at the last set of published results that the carrier ethernet business which should have been a strongpoint in networking sales collapsed which did them no favours in last H1 figures.
There is mention of that issue here.

"Networking: Positioned for growth
The Networking division has faced challenges due to a global slowdown in telecommunications spending. Yet, green shoots are suggesting a recovery. BATM continues to secure significant contracts while expanding its innovative Edgility platform, which enables the management of applications and devices at the edge of networks.

Edgility has found favour with high-profile customers like Totalplay, a major telecommunications provider in Mexico, and Cemex, a global building materials leader. These partnerships highlight the platform’s scalability and potential for recurring revenue.

Additionally, Edgility’s designation as an Amazon Web Services Qualified Software Partner boosts its reach, giving BATM access to AWS’s expansive customer base. A stronger second half is expected, underpinned by new orders for carrier ethernet products and continued adoption of Edgility. Investments in mobile backhaul solutions and next-generation products position the division well to capture future demand."

[fse] 11/12/2024 15:55

Here we go again.



"For 2024, BATM is on track to deliver strong full-year growth. The Cyber division leads the charge, with Networking set to recover and Diagnostics poised for sustained expansion.

The commercialisation of BATM’s cybersecurity solutions represents a transformative moment, significantly broadening its revenue potential. This, combined with advancements in diagnostics and a rebound in telecommunications, positions the company for long-term success.

As ShoreCap noted, BATM’s current valuation does not reflect its substantial upside potential. With multiple inflexion points on the horizon and a robust strategy in place, the group presents an enticing opportunity for investors seeking exposure to high-growth, technology-driven markets."

[fse] 11/12/2024 15:50

This is actually a major step forwards.
It's the point a new technology goes from the bench to the market and belive me this is point where a lot of promising technologies fail. They are gingerly past that point.
The science of the system was first put to test apparently successfully with acceptable accuracy readings. My understanding is that this is the now the unit that they will use to sell the product. ie Its a move from Lab type settings to actual machine in actual hospital setting.
It also means that at this stage they can start to go after potential customers and as they say partnerships.
I am not aware of any other company in the field of molecular diagnostics using Isothermal amplification to advance accuracy and speed of sampling.

The other positive is that us long suffering shareholders who doubtless have developed ulcers holding shares in this company can be diagnosed by the same company that gave them the wretched ulcer in the first place.

[resistance1] 11/12/2024 11:03

It is the work on the new Stomach ulcer panel and $1m funding

[paulisi] 11/12/2024 10:33

It's as if they are writing up the report for the interims and have forgotten to announce the RNS...

[kooba] 11/12/2024 10:32

Which begs the question why rns it now ? Maybe it's the $500k a year grant funding but again hardly price sensitive.What they really need to do is guide to when they might be able to sell this product in a mass market...or even smaller markets like Israel...if they feel they need to announce something already known at least provide the context in terms of its potential commercial adoption at which point the market might wake up to the possibilities that were so exciting 5 years ago.Looking at markets in general and smaller Co's there is no appetite for patient investing..BATM shareholders have been patient it appears to me and that patience is wearing very thin.Nb Edgility has been available to the global markets for years but it doesn't mean instant sales or even sales growth in a burgeoning market place apparently Telco is getting chicken feed. As BATM keep pointing out the markets they face are growing very rapidly ..just they are not participating!

[resistance1] 11/12/2024 10:12

The commencement of the Rome trial is old news. I think you and I discussed in a few months back. Dr Eran shared photos of it starting in Rome at the time. From what I understand trial for equipment is completely different than drug trials. Shorter and to a lower threshold. Earlier this year it was stated trials were completing end '24. So this perhaps is a 3-4 month trial duration. They will run Natlab alongside the existing far slower and more costly diagnosis methodology usually carried out in labs away from the clinical setting. At the end of the period they will be able to compare the results from both approaches. Natlab has already been validated in Israel and there is no reason to believe that the outcome will be substandard here.

What is news is the $1m grant to develop a new panel. Another string to the Natlab capability at no cost to BATM. Income will come from the sale of machines but much more importantly, the regular sale of consumables, the panels themselves. The many different panels will make Natlab a 'one stop in hospital diagnosis solution.' From the 2023 investor presentation they did a competitive cost/benefit table, and Natlab's diagnosis was faster and cheaper than all the listed alternatives -- we of course don't know if the competitors were 'cherry-picked' but hey ho.

[kooba] 11/12/2024 09:34

This is highlighting "..commencement of NATlab pre-clinical validation"Pre-clinical in drug development terms means before you test it on humans ..it's rather unclear here with a diagnostic product how such devices are trialled and validated in a pre-clinical way.Are there further trials after pre-clinical validation before...clinical ?They are pointing to sales ahead of EU approval..where from and what about the all important US market?"Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market."And how long would regulatory approval take??"One of the key issues with the current regulations is the complexity and length of the regulatory procedures, which have led to delays in the certification and approval of medical devices and in vitro diagnostics. This has particularly impacted small and medium-sized enterprises (SMEs), resulting in shortages of medical devices and restricting patient access to innovative and life-saving technologies. "https://www.osborneclarke.com/insights/european-parliament-urges-revision-medical-devices-regulations

[kooba] 11/12/2024 07:40

April 2019..Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are delighted to have received the Initial Investment to accelerate the commercialisation of our breakthrough NATlab system, which we believe will revolutionise the point-of-care medical diagnostics industry. Since signing the Investment Agreement, we have continued to make progress in our final preparations ahead of in-hospital installation. We are very excited about the tremendous potential of this unique molecular biology-based diagnostics solution."https://www.batm.com/rns-rnr/posts/2019/april/receipt-of-145m-investment-in-ador-diagnostics/Not sure how long very excited can last ...I guess that the market has also changed somewhat in 5 years so am unclear what products have been developed and actually reached the market in the past 5 years...the pace that Batm works seems snail paced in fast moving areas.

[wizzkid211] 11/12/2024 07:38

paulisi the one million grant was not factored in, i know its not much

[paulisi] 11/12/2024 07:23

I'm certain this announcement is already factored into the price.What I don't know is the timeliness for the next phase and what the plan in to go to market. BATM are not good at selling their new products....

[kooba] 11/12/2024 07:22

Whilst today's news is encouraging that something is actually happening with what has been a large investment and is meant to be a major growth driver for the business..how much news is it really. Also there is no indication as to how long this phase of validation will take before it then seeks regulatory approval before the company can commercially sell a product. Still sounds some way off and seems well behind initial timetables given."ADOR Diagnostics successfully completed pre-clinical trials of the NATlab and is preparing for the next phase of validation at a leading hospital in Italy"August 2024 interims.

[wizzkid211] 11/12/2024 07:02

11 December 2024



BATM Advanced Communications Limited

("BATM" or "the Group")



Key milestone achieved with commencement of NATlab pre-clinical validation

Latest phase begins at major Italian hospital following successful completion of pre-clinical trials



BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce that the NATlab molecular biology platform being developed by ADOR Diagnostics ("ADOR"), an associate company of the Group, has commenced pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy. This marks a key milestone in the development of NATlab and, the Group believes, will enable initial sales as well as increase industry awareness and interest from prospective partners.



The advanced NATlab molecular biology platform is a point-of-care sample-to-answer solution designed to provide rapid and accurate diagnosis of infectious disease. It uses a patented isothermal amplification method for syndromic multiplex diagnostics to be able to rapidly identify a broad range of pathogens from a single test.



The commencement of the pre-clinical validation phase follows the successful completion of pre-clinical trials, which were conducted at the Tzafom Medical Center in Israel, to confirm the validity of the biological process that ADOR has developed and that it can be performed within the NATlab cartridge and analyser device. NATlab identified all negative samples and had a 97% sensitivity for the positive samples, confirming the efficacy of the system and its ability to out-perform competing solutions available in the market today because of its multiplex diagnostic capability for rapid and accurate diagnosis.



ADOR has now made significant progress with NATlab with the full system entering the pre-clinical validation phase at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market.



In addition, following the success of the pre-clinical trials, ADOR, in collaboration with the Tzafom Medical Center, has received a grant from the Israel Innovation Authority to develop a NATlab panel for the diagnosis of stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is to be granted over two years based on the achievement of milestones.



Moti Nagar, Chief Executive Officer of BATM, said: "The commencement of the pre-clinical validation phase at a major European hospital is an important milestone in the development of NATlab and represents a key stage towards enabling its market entry. This also follows the successful completion of pre-clinical trials, which delivered excellent results. As the value of the substantial IP that has been built within ADOR continues to increase as well as the industry awareness of the attractiveness of the NATlab solution, we remain excited about its prospects and look forward to reporting on further progress."

[car1pet] 10/12/2024 21:56

Why us it silly. The Ceo and FF are incompetent. 2 years and share price down from 30p to 18/19p is unacceptable

Needs to be taken over by a competent nansgemt team who understand hiw to sell

[kemche] 10/12/2024 21:19

Levering up the balance sheet is a simple but fascinating possibility, Resistance, as it wouldn't just be equity-friendly for the obvious reasons - ie., the purpose of the capital raise is a clearly articulated, value-creating investment as you describe - but would also be a signal to the market that management are all at once breaking from the Company's overly cautious approach of the past to the capital structure, AND that they are increasingly confident around FCF generation going forward. I am pretty tough on certain posters who periodically rant that a total overall of senior management is the 'only' way forward for BATM, which is clearly silly, but levering up the balance sheet at this stage with market rates starting to ease, in order to get one of their key businesses the scale it needs, would indeed demonstrate that Moti has clearly left the Zvi era behind.

[echoridge] 09/12/2024 10:18

Healthy buyer out there today. Still my stock pick of the year so it’s got to get a move on

[resistance1] 06/12/2024 08:39

A brand new report that supports what Kooba is saying about the buoyant Tase125 and the tech sector in Israel. Hoping some of this comes our way: Israeli tech M&A deals reach new peak - report
According to Vintage Investment Partners, M&A deals reached a new record of this year of $10.5 billion, 22% higher than the previous peak in 2021.